These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 9378161)

  • 21. The diagnostic value of 18F-FDG PET/CT in association with serum tumor marker assays in breast cancer recurrence and metastasis.
    Dong Y; Hou H; Wang C; Li J; Yao Q; Amer S; Tian M
    Biomed Res Int; 2015; 2015():489021. PubMed ID: 25879025
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Assessment of CA 15.3, CEA and TPA concentrations during monitoring of breast cancer.
    Sölétormos G; Petersen PH; Dombernowsky P
    Clin Chem Lab Med; 2000 May; 38(5):453-63. PubMed ID: 10952230
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Circulating tumor marker levels in advanced breast carcinoma correlate with the extent of metastatic disease.
    Colomer R; Ruibal A; Salvador L
    Cancer; 1989 Oct; 64(8):1674-81. PubMed ID: 2790682
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical value of CA 15-3, mucin-like carcinoma-associated antigen, tumor polypeptide antigen, and carcinoembryonic antigen in monitoring early breast cancer patients.
    Pectasides D; Pavlidis N; Gogou L; Antoniou F; Nicolaides C; Tsikalakis D
    Am J Clin Oncol; 1996 Oct; 19(5):459-64. PubMed ID: 8823487
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Tumor markers in liver metastases of colorectal carcinoma].
    Moreno Sierra J; Vincent E; Gea M; Ortega MD; Borque M; Madrigal J; Pimentel C; Represa J
    Rev Esp Enferm Dig; 1990 Sep; 78(3):139-44. PubMed ID: 1980590
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of tumor markers in southern Indian breast cancer patients.
    Porika M; Malotu N; Veldandi UK; Yadala N; Abbagani S
    Asian Pac J Cancer Prev; 2010; 11(1):157-9. PubMed ID: 20593949
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sensitivity of CA 15-3, CEA and serum HER2 in the early detection of recurrence of breast cancer.
    Pedersen AC; Sørensen PD; Jacobsen EH; Madsen JS; Brandslund I
    Clin Chem Lab Med; 2013 Jul; 51(7):1511-9. PubMed ID: 23403727
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Utility of CA 15-3 and CEA in monitoring breast cancer patients with bone metastases: special emphasis on "spiking" phenomena.
    Yasasever V; Dinçer M; Camlica H; Karaloğlu D; Dalay N
    Clin Biochem; 1997 Feb; 30(1):53-6. PubMed ID: 9056110
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Plasma mammaglobin messenger RNA in breast cancer patients as an addition to serum tumor.
    El-Attar NI; Gaefar HA
    Egypt J Immunol; 2007; 14(2):111-21. PubMed ID: 20306663
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical evaluation of potential usefulness of CEA, CA 15-3, and MCA in follow-up of breast cancer patients.
    Jezersek B; Cervek J; Rudolf Z; Novaković S
    Cancer Lett; 1996 Dec; 110(1-2):137-44. PubMed ID: 9018092
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Importance of CEA and CA 15-3 during disease progression in metastatic breast cancer patients.
    Laessig D; Nagel D; Heinemann V; Untch M; Kahlert S; Bauerfeind I; Stieber P
    Anticancer Res; 2007; 27(4A):1963-8. PubMed ID: 17649806
    [TBL] [Abstract][Full Text] [Related]  

  • 32. c-erbB-2 oncoprotein, CEA, and CA 15.3 in patients with breast cancer: prognostic value.
    Molina R; Jo J; Filella X; Zanon G; Pahisa J; Mu noz M; Farrus B; Latre ML; Escriche C; Estape J; Ballesta AM
    Breast Cancer Res Treat; 1998 Sep; 51(2):109-19. PubMed ID: 9879773
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Value of CA 15.3 in breast cancer and comparison with CEA and TPA: a study of specificity in disease-free follow-up patients and sensitivity in patients at diagnosis of the first metastasis.
    Vizcarra E; Lluch A; Cibrián R; Jarque F; Alberola V; Belloch V; García-Conde J
    Breast Cancer Res Treat; 1996; 37(3):209-16. PubMed ID: 8825132
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An updated evaluation of serum sHER2, CA15.3, and CEA levels as biomarkers for the response of patients with metastatic breast cancer to trastuzumab-based therapies.
    Perrier A; Boelle PY; Chrétien Y; Gligorov J; Lotz JP; Brault D; Comperat E; Lefèvre G; Boissan M
    PLoS One; 2020; 15(1):e0227356. PubMed ID: 31910438
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Serum tumor markers in metastatic breast cancer and course of disease.
    Caffier H; Brandau H
    Cancer Detect Prev; 1983; 6(4-5):451-7. PubMed ID: 6197167
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of bone scanning and CA 15-3 serum concentration in the follow-up of breast cancer.
    Montravers F; Younsi N; Rousseau C; Philippe C; Seddiki M; Uzan S; Izrael V; Talbot JN
    Anticancer Res; 1997; 17(3B):1683-6. PubMed ID: 9179218
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The value of the tumor marker CA 15-3 in diagnosing and monitoring breast cancer. A comparative study with carcinoembryonic antigen.
    Safi F; Kohler I; Röttinger E; Beger H
    Cancer; 1991 Aug; 68(3):574-82. PubMed ID: 2065278
    [TBL] [Abstract][Full Text] [Related]  

  • 38. BR-MA, OM-MA, GI-MA and CEA: clinical evaluation using the IMMULITE analyzer.
    van Dalen A
    Tumour Biol; 1999; 20(3):117-29. PubMed ID: 10213919
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical significance of cancer antigen, CA 15.3 in breast cancer.
    Muthuswamy S; Raste AS
    Indian J Med Sci; 2000 Oct; 54(10):442-7. PubMed ID: 11262861
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Elevated CA125 in breast cancer--A sign of advanced disease.
    Norum LF; Erikstein B; Nustad K
    Tumour Biol; 2001; 22(4):223-8. PubMed ID: 11399947
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.